A double‑blind RCT is testing low‑dose naltrexone (1–4.5 mg) for Post‑COVID Fatigue Syndrome (160 pts, 16 weeks). Sponsored by Luis Nacul (UBC); aims: reduce fatigue, symptoms, inflammatory markers. Details: https://clinicaltrials.gov/study/NCT05430152 🧪🩺 #LongCOVID #PCFS #ClinicalTrials